Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Clinical Medicine Année : 2020

Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life

(1) , (1) , , (2) , , , (1) , (1) , (2, 3) , (2, 4) , (2)
1
2
3
4

Résumé

Background: Janus kinase inhibitors (JAKis) represent a new alternative to treat rheumatoid arthritis (RA). The objective of this study was to evaluate the effectiveness, tolerance profile, and maintenance of these treatments (tofacitinib and baricitinib) in real life. Methods: All patients in the rheumatology department of Amiens University Hospital treated by JAKis for RA were included from 1 October 2017 to 20 May 2020. Clinical and biological data were provided retrospectively in this observational and single-center study. We aimed to study the JAKi maintenance rate at 12 months and their clinical and biological safety profiles. Results: Fifty-five patients were included. Drug maintenance at 12 months was 67.6%. Factors associated with poorer maintenance were a higher Charlson comorbidity index (HR 1.311 (1.089-1.579); p = 0.0042), a higher age (HR 1.055 (1.015-1.096); p = 0.0067), and corticosteroids therapy at initiation (HR 2.722 (1.006-7.365); p = 0.0487). The clinical and biological safety profile was generally good. Conclusions: Our study found that a higher Charlson index, age, and corticosteroids appeared to be associated with the earlier discontinuation of treatment. JAKis had a response and tolerance profile in real life at least equivalent to that of biological disease-modifying antirheumatic drugs (bDMARDs).

Dates et versions

hal-03551522 , version 1 (01-02-2022)

Identifiants

Citer

Valentine Deprez, Laure Le Monnier, Jean-Marc Sobhy-Danial, Franck Grados, Isabelle Henry-Desailly, et al.. Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life. Journal of Clinical Medicine, 2020, 9 (10), ⟨10.3390/jcm9103319⟩. ⟨hal-03551522⟩
12 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More